EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccine

Solfrid Thunold iD, Eivor Hernes, Saima Farooqi, Åsa Kristina Öjlert, Roslyn J Francis, Anna K Nowak, Weronika Maria Szejniuk, Søren Steen Nielsen, Susana Cedres, Marc Simo Perdigo, Jens Benn Sørensen, Carin Meltzer und 4 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2025

DOI: 10.1007/s00259-024-06853-0 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Solfrid Thunold und 15 weiteren Autor:innen. Beteiligte Einrichtung: Dept of Oncology, Oslo University Hospital, Oslo, Norway. solthu@ous-hf.no. Hauptthemen laut MEDLINE: Cancer Vaccines, Fluorodeoxyglucose F18, Ipilimumab, Mesothelioma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Helse Sør-Øst RHF.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The introduction of immunotherapy in pleural mesothelioma (PM) has highlighted the need for effective outcome predictors. This study explores the role of [18F]FDG PET/CT in predicting outcomes in PM treated with immunotherapy.

Methods

Patients from the NIPU trial, receiving ipilimumab and nivolumab +/- telomerase vaccine in second-line, were included. [18F]FDG PET/CT was obtained at baseline (n = 100) and at week-5 (n = 76). Metabolic tumour volume (MTV) and peak standardised uptake value (SUV peak ) were evaluated in relation to survival outcomes. Wilcoxon rank-sum test was used to assess differences in MTV, total lesion glycolysis (TLG), maximum standardised uptake value (SUV max ) and SUV peak between patients exhibiting an objective response, defined as either partial response or complete response according to the modified Response Criteria in Solid Tumours (mRECIST) and immune RECIST (iRECIST), and non-responders, defined as either stable disease or progressive disease as their best overall response.

Results

Univariate Cox regression revealed significant associations of MTV with OS (HR 1.36, CI: 1.14, 1.62, p < 0.001) and PFS (HR 1.18, CI: 1.03, 1.34, p = 0.02), while multivariate analysis showed a significant association with OS only (HR 1.35, CI: 1.09, 1.68, p = 0.007). While SUV peak was not significantly associated with OS or PFS in univariate analyses, it was significantly associated with OS in multivariate analysis (HR 0.43, CI: 0.23, 0.80, p = 0.008). Objective responders had significant reductions in TLG, SUV max and SUV peak at week-5.

Conclusion

MTV provides prognostic value in PM treated with immunotherapy. High SUV peak was not associated with inferior outcomes, which could be attributed to the distinct mechanisms of immunotherapy. Early reductions in PET metrics correlated with treatment response. Study registration The NIPU trial (NCT04300244) is registered at clinicaltrials.gov. https://classic.clinicaltrials.gov/ct2/show/NCT04300244?cond=Pleural+Mesothelioma&cntry=NO&draw=2&rank=4

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer VaccinesFluorodeoxyglucose F18IpilimumabMesotheliomaNivolumabPleural NeoplasmsPositron Emission Tomography Computed TomographyTelomeraseAgedAged, 80 and overFemaleHumansMaleMiddle AgedMesothelioma, MalignantTreatment Outcome

Stichwörter der Autor:innen

ImmunotherapyMTVPleural mesotheliomaSUVTelomerase vaccine[18F]FDG PET

Substanzen

Cancer VaccinesFluorodeoxyglucose F18IpilimumabNivolumabTelomerase

Autor:innen und Institutionen

  • Dept of Oncology, Oslo University Hospital, Oslo, Norway. solthu@ous-hf.no.
  • Dept of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway. solthu@ous-hf.no.
  • Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.
  • Dept of Oncology, Oslo University Hospital, Oslo, Norway.
  • Dept of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
  • Dept of Nuclear Medicine, Sir Charles Gairdner Hospital, Perth, Australia.

ORCID-Profile: Solfrid Thunold

Förderung

  • Helse Sør-Øst RHF

Zitieren

APA

Thunold, S., Hernes, E., Farooqi, S., Öjlert, Å. K., Francis, R. J., Nowak, A. K., Szejniuk, W. M., Nielsen, S. S., Cedres, S., Perdigo, M. S., Sørensen, J. B., Meltzer, C., Mikalsen, L. T. G., Helland, Å., Malinen, E., & Haakensen, V. D. (2025). Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccine. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-06853-0

Vancouver

Thunold S, Hernes E, Farooqi S, Öjlert ÅK, Francis RJ, Nowak AK, et al. Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccine. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-024-06853-0

BibTeX
@article{Thunold2025,
  author = {Thunold, Solfrid and Hernes, Eivor and Farooqi, Saima and Öjlert, Åsa Kristina and Francis, Roslyn J and Nowak, Anna K and Szejniuk, Weronika Maria and Nielsen, Søren Steen and Cedres, Susana and Perdigo, Marc Simo and Sørensen, Jens Benn and Meltzer, Carin and Mikalsen, Lars Tore Gyland and Helland, Åslaug and Malinen, Eirik and Haakensen, Vilde Drageset},
  title = {Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccine},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  doi = {10.1007/s00259-024-06853-0}
}
Kostenlos starten →